469.65
price down icon0.55%   -2.62
after-market アフターアワーズ: 469.65
loading
前日終値:
$472.27
開ける:
$472.66
24時間の取引高:
1.18M
Relative Volume:
0.79
時価総額:
$120.60B
収益:
$11.10B
当期純損益:
$-988.90M
株価収益率:
-119.81
EPS:
-3.92
ネットキャッシュフロー:
$-1.26B
1週間 パフォーマンス:
+2.14%
1か月 パフォーマンス:
+5.35%
6か月 パフォーマンス:
+6.83%
1年 パフォーマンス:
-4.59%
1日の値動き範囲:
Value
$465.84
$472.71
1週間の範囲:
Value
$456.83
$480.00
52週間の値動き範囲:
Value
$377.85
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
名前
Vertex Pharmaceuticals Inc
Name
セクター
Healthcare (1164)
Name
電話
(617) 341-6393
Name
住所
50 NORTHERN AVENUE, BOSTON, MA
Name
職員
6,100
Name
Twitter
@VertexPharma
Name
次回の収益日
2025-02-10
Name
最新のSEC提出書
Name
VRTX's Discussions on Twitter

VRTX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-07 ダウングレード Wolfe Research Outperform → Peer Perform
2025-05-06 ダウングレード Leerink Partners Outperform → Market Perform
2025-04-22 再開されました Cantor Fitzgerald Overweight
2025-02-12 アップグレード Canaccord Genuity Sell → Hold
2025-02-11 アップグレード Canaccord Genuity Sell → Hold
2025-01-30 ダウングレード Wells Fargo Overweight → Equal Weight
2024-12-20 繰り返されました H.C. Wainwright Buy
2024-12-19 ダウングレード Oppenheimer Outperform → Perform
2024-12-09 アップグレード Jefferies Hold → Buy
2024-11-14 開始されました Citigroup Buy
2024-10-16 開始されました Scotiabank Sector Perform
2024-10-10 再開されました Raymond James Mkt Perform
2024-08-05 ダウングレード Barclays Overweight → Equal Weight
2024-06-27 開始されました Redburn Atlantic Buy
2024-04-11 アップグレード Evercore ISI In-line → Outperform
2024-02-15 開始されました Wolfe Research Outperform
2024-02-06 ダウングレード Evercore ISI Outperform → In-line
2024-02-02 ダウングレード Bernstein Outperform → Mkt Perform
2024-01-31 ダウングレード Maxim Group Buy → Hold
2024-01-31 ダウングレード Robert W. Baird Neutral → Underperform
2024-01-24 ダウングレード Canaccord Genuity Hold → Sell
2023-12-14 繰り返されました RBC Capital Mkts Sector Perform
2023-05-30 開始されました William Blair Outperform
2023-05-04 再開されました Piper Sandler Overweight
2023-03-21 開始されました Bernstein Outperform
2023-01-18 開始されました Canaccord Genuity Hold
2023-01-17 アップグレード SVB Leerink Mkt Perform → Outperform
2022-12-19 ダウングレード Jefferies Buy → Hold
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-01 アップグレード Maxim Group Hold → Buy
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-05-06 ダウングレード Robert W. Baird Outperform → Neutral
2022-05-03 アップグレード Morgan Stanley Underweight → Equal-Weight
2022-02-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2022-01-27 繰り返されました JP Morgan Overweight
2022-01-27 繰り返されました Morgan Stanley Underweight
2022-01-27 繰り返されました RBC Capital Mkts Outperform
2022-01-27 繰り返されました Stifel Hold
2022-01-27 繰り返されました Wolfe Research Outperform
2022-01-20 アップグレード BMO Capital Markets Market Perform → Outperform
2021-12-09 開始されました Wells Fargo Overweight
2021-11-19 開始されました BMO Capital Markets Market Perform
2021-11-19 ダウングレード Piper Sandler Overweight → Neutral
2021-09-09 ダウングレード Stifel Buy → Hold
2021-09-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2021-07-20 ダウングレード SVB Leerink Mkt Perform → Underperform
2021-07-19 再開されました Wolfe Research Outperform
2021-07-01 開始されました Raymond James Mkt Perform
2021-06-11 ダウングレード Daiwa Securities Outperform → Neutral
2021-02-23 アップグレード Robert W. Baird Neutral → Outperform
2021-02-02 繰り返されました H.C. Wainwright Buy
2020-12-30 開始されました Daiwa Securities Outperform
2020-11-30 アップグレード RBC Capital Mkts Sector Perform → Outperform
2020-11-20 開始されました Bernstein Outperform
2020-10-28 開始されました UBS Buy
2020-07-31 繰り返されました H.C. Wainwright Buy
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-04-30 繰り返されました H.C. Wainwright Buy
2020-04-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-03-04 開始されました Barclays Overweight
2020-01-31 ダウングレード Robert W. Baird Outperform → Neutral
2019-11-19 アップグレード Guggenheim Neutral → Buy
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-09-03 アップグレード Goldman Neutral → Buy
2019-08-01 ダウングレード Needham Buy → Hold
2019-05-23 再開されました Citigroup Buy
2019-05-21 開始されました Credit Suisse Outperform
2019-04-12 開始されました Evercore ISI In-line
2019-03-26 アップグレード William Blair Mkt Perform → Outperform
2019-03-19 ダウングレード SVB Leerink Outperform → Mkt Perform
2019-02-06 ダウングレード Maxim Group Buy → Hold
すべてを表示

Vertex Pharmaceuticals Inc (VRTX) 最新ニュース

pulisher
07:05 AM

How does Vertex Pharmaceuticals Incorporated generate profit in a changing economyRobust financial gains - jammulinksnews.com

07:05 AM
pulisher
04:06 AM

Why is Vertex Pharmaceuticals Incorporated stock attracting strong analyst attentionInvest confidently with real-time data - jammulinksnews.com

04:06 AM
pulisher
12:53 PM

Published on: 2025-07-27 22:21:17 - jammulinksnews.com

12:53 PM
pulisher
12:07 PM

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment - MSN

12:07 PM
pulisher
12:06 PM

Is Vertex Pharmaceuticals Incorporated a growth stock or a value stockSuperior portfolio returns - jammulinksnews.com

12:06 PM
pulisher
11:53 AM

Should I hold or sell Vertex Pharmaceuticals Incorporated stock in 2025Free Stock Market Forecast Reports - jammulinksnews.com

11:53 AM
pulisher
Jul 26, 2025

Truist Financial Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Jul 26, 2025
pulisher
Jul 26, 2025

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - MSN

Jul 26, 2025
pulisher
Jul 25, 2025

Vertex Bets Big On Rare Diseases And Pain Medicine - Finimize

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Vertex Pharmaceuticals Incorporated stock priceHigh-octane financial growth - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Can Vertex Pharmaceuticals Incorporated stock recover from recent declineFree Risk Assessment Services - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Three Indian American-led firms among TIME100 Most Influential Companies - The American Bazaar

Jul 24, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Vertex Pharmaceuticals Incorporated stockFree Stock Market Return Analysis - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi - The Globe and Mail

Jul 23, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals: Pioneering Orphan Drug Innovation in Cystic Fibrosis and Cementing Market Leadership - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis - The Malaysian Reserve

Jul 22, 2025
pulisher
Jul 22, 2025

Is Vertex Pharmaceuticals Incorporated a good long term investmentTriple-digit wealth increases - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals (VRTX) Gets a Hold from Wells Fargo - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need To Know - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - Yahoo Finance

Jul 22, 2025
pulisher
Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 21, 2025
pulisher
Jul 21, 2025

3 Monster Stocks in the Making to Buy Right Now - The Motley Fool

Jul 21, 2025
pulisher
Jul 18, 2025

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga

Jul 18, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals: Strong Growth Driven by Cystic Fibrosis Success and Strategic Expansions - TipRanks

Jul 16, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals Surges to 213th in Trading Volume with $460 Million in Shares Traded Despite Stock Price Decline - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug - BioPharma Dive

Jul 15, 2025
pulisher
Jul 15, 2025

Peripheral Neuropathic Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Trevena, Afasci, Lexicon Pharma, Haisco Pharma, Vertex Pharma - Barchart.com

Jul 15, 2025
pulisher
Jul 15, 2025

EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex secures NHS deal for once-daily cystic fibrosis therapy - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE - PMLiVE

Jul 15, 2025

Vertex Pharmaceuticals Inc (VRTX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$563.10
price down icon 0.27%
$328.81
price up icon 0.25%
$591.99
price up icon 0.04%
biotechnology ONC
$291.47
price down icon 1.68%
$115.31
price up icon 0.65%
大文字化:     |  ボリューム (24 時間):